UroGen Gets FDA Nod for Low-Grade Upper Tract Urothelial Cancer Drug

The FDA on Wednesday approved a drug developed by UroGen Pharma to treat low-grade upper tract urothelial cancer, which rarely spreads but often recurs and can cause kidney damage in some patients.